E-Learning

(Bloomberg) -- Catastrophe-bond issuance rose to a record this year, increasing the overall market to almost $50 billion, as insurers transferred more risk from costly climate disasters to private investors.Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife

(Bloomberg) -- Three of the world’s biggest companies have had their influence reduced in the Nasdaq 100 Index after the giant technology rally of 2024 swelled them to unprecedented size.Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayThe Architects Who Built MiamiReviving a Little-Known Modernist Landmark in BuffaloNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisTesla Inc., M

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

From a changing consumer, to an unsteady regulatory environment and the entry of a heavy hitter, e-commerce has had to adapt to stay agile.

Major U.S. indexes were mixed at midday Monday to start the holiday-shortened trading week.

Stock market pros expect more muted gains in 2025 compared to the past few years.

Veteran trader Stephen 'Sarge' Guilfoyle is placing his bets on a familiar technology name in 2025.

LMT's 320-day moving average has acted as a springboard in the past

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria

Playa Hotels' shares surged Monday after the resort operator said it has entered into an agreement to explore a potential acquisition by Hyatt Hotels.